📊 MREO Key Takeaways
Is Mereo BioPharma Group plc (MREO) a Good Investment?
Mereo is a pre-commercial pharmaceutical company burning $8.8M in annual operating losses against minimal $500K revenue, indicating an unproven clinical-stage pipeline with no commercial viability demonstrated. While the $36.2M cash position and zero debt provide ~8 years of runway, the company shows no evidence of revenue growth, market traction, or clear path to profitability without successful drug development.
Mereo BioPharma is a pre-revenue, R&D-stage company with extreme negative margins and large operating losses despite a modest YoY improvement in net loss/EPS. While the balance sheet is clean and liquid (debt-free, >10x current ratio), the current burn (~$31M OCF) implies a roughly 12–18 month runway absent new funding or material revenue. On fundamentals, financing risk and lack of revenue visibility outweigh near-term improvement.
Why Buy Mereo BioPharma Group plc Stock? MREO Key Strengths
- Substantial cash position of $36.2M representing 89% of total assets, providing substantial development runway
- Zero debt with only $6.6M total liabilities, eliminating leverage and financial distress risk
- Exceptional liquidity (6.48x current ratio) enabling uninterrupted R&D operations without external funding pressure
- Debt-free balance sheet with minimal liabilities
- Strong liquidity and cash reserves (10.46x current ratio)
- Asset-light model with negligible capex
MREO Stock Risks: Mereo BioPharma Group plc Investment Risks
- Catastrophic operating loss of -$8.8M against $500K revenue reveals pre-commercial stage with unproven products and no market validation
- Operating cash burn of -$4.3M annually while depleting cash reserves despite current cushion shortens development timeline
- Near-zero revenue and negative operating margins indicate complete absence of commercial traction or adopted products in marketplace
- Sustained cash burn likely requiring external financing/dilution within ~1–2 years
- Extreme negative margins and poor returns (ROE/ROA) with minimal revenue
- Execution and regulatory risk to advance pipeline to commercialization
Key Metrics to Watch
- Quarterly revenue growth and first evidence of commercial product sales
- Operating cash burn rate trend to assess remaining development runway
- Clinical trial advancement, regulatory approvals, and partnership announcements validating pipeline progress
- Cash & equivalents and estimated runway
- Operating cash flow and operating expense trajectory
Mereo BioPharma Group plc (MREO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.48x current ratio provides a solid financial cushion.
MREO Profit Margin, ROE & Profitability Analysis
MREO vs Healthcare Sector: How Mereo BioPharma Group plc Compares
How Mereo BioPharma Group plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mereo BioPharma Group plc Stock Overvalued? MREO Valuation Analysis 2026
Based on fundamental analysis, Mereo BioPharma Group plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mereo BioPharma Group plc Balance Sheet: MREO Debt, Cash & Liquidity
MREO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mereo BioPharma Group plc's revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-0.06 indicates the company is currently unprofitable.
MREO Revenue Growth, EPS Growth & YoY Performance
MREO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$7.0M | $-0.01 |
| Q2 2025 | N/A | -$9.0M | $-0.02 |
| Q3 2024 | N/A | -$1.8M | $-0.01 |
| Q2 2024 | N/A | -$1.8M | $0.00 |
| Q1 2024 | N/A | -$9.0M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Mereo BioPharma Group plc Dividends, Buybacks & Capital Allocation
MREO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mereo BioPharma Group plc (CIK: 0001719714)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MREO
What is the AI rating for MREO?
Mereo BioPharma Group plc (MREO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MREO's key strengths?
Claude: Substantial cash position of $36.2M representing 89% of total assets, providing substantial development runway. Zero debt with only $6.6M total liabilities, eliminating leverage and financial distress risk. ChatGPT: Debt-free balance sheet with minimal liabilities. Strong liquidity and cash reserves (10.46x current ratio).
What are the risks of investing in MREO?
Claude: Catastrophic operating loss of -$8.8M against $500K revenue reveals pre-commercial stage with unproven products and no market validation. Operating cash burn of -$4.3M annually while depleting cash reserves despite current cushion shortens development timeline. ChatGPT: Sustained cash burn likely requiring external financing/dilution within ~1–2 years. Extreme negative margins and poor returns (ROE/ROA) with minimal revenue.
What is MREO's revenue and growth?
Mereo BioPharma Group plc reported revenue of $500.0K.
Does MREO pay dividends?
Mereo BioPharma Group plc does not currently pay dividends.
Where can I find MREO SEC filings?
Official SEC filings for Mereo BioPharma Group plc (CIK: 0001719714) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MREO's EPS?
Mereo BioPharma Group plc has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MREO a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mereo BioPharma Group plc has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MREO stock overvalued or undervalued?
Valuation metrics for MREO: ROE of -19.7% (sector avg: 15%), net margin of -1,343.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MREO stock in 2026?
Our dual AI analysis gives Mereo BioPharma Group plc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MREO's free cash flow?
Mereo BioPharma Group plc's operating cash flow is $-4.3M, with capital expenditures of $0.0. FCF margin is -862.4%.
How does MREO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,343.8% (avg: 12%), ROE -19.7% (avg: 15%), current ratio 6.48 (avg: 2).